Doctors News Hubb
Advertisement Banner
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
Doctors News Hubb
No Result
View All Result
Home News

Castration-sensitive Prostate Cancer, SPOP Mutations Predict Receptor Axis–Targeted Therapy

admin by admin
December 29, 2022
in News


The following is a summary of “SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer” published in the November 2022 issue of Clinical Cancer by Swami et al.


Patients with castration-sensitive metastatic prostate cancer are typically treated with docetaxel or androgen receptor axis-targeted treatments (ARAT) to intensify androgen deprivation therapy (ADT), metastatic castration-sensitive prostate cancer (mCSPC). Nonetheless, there are no readily available biomarkers to help doctors decide which therapies to use. Researchers expected that patients with de novo (dn)-mCSPC who carried SPOP mutations would benefit from ADT intensification with ARAT but not docetaxel. Between January 2011 and December 2021, investigators pulled patient-level data from a deidentified national (U.S.-based) prostate cancer clinico-genomic database.

Eligibility requirements include a diagnosis of metastatic disease within 30 days of the initial diagnosis of prostate cancer, genomic profiling of a tissue biopsy taken within 90 days of the initial diagnosis, and commencement with ARAT or docetaxel within 120 days of the initial diagnosis. Overall survival (OS) and the time it took for prostate cancer to become resistant to ADT in patients with and without SPOP mutations who had ADT intensification with ARAT or docetaxel were compared using the log-rank test and Cox proportional hazards models.

In the ARAT cohort, the presence of a SPOP mutation was linked to better overall survival (OS) (not reached vs. 27.2 months; aHR, 0.19; 95% CI, 0.05-0.79; P=0.022) and progression-free survival (PFS) (NR vs. 16.7 months; aHR, 0.20; 95% CI, 0.06-0.63; P=0.006). In the docetaxel-treated cohort, SPOP mutation status was not related to TTCRPC or OS. Patients with dn-mCSPC with a SPOP mutation had a better response to ADT plus ARAT (but not to ADT plus docetaxel) in the real world. This has the potential to be a predictive biomarker for the selection of treatment for patients with mCSPC.

Source; aacrjournals.org/clincancerres/article-abstract/28/22/4917/710455/SPOP-Mutations-as-a-Predictive-Biomarker-for?redirectedFrom=fulltext



Source link

Advertisement Banner
Previous Post

Setting EMS Training Resolutions for You and Your Team in 2023

Next Post

Leveraging Digital Twins for Transforming Healthcare – The Health Care Blog

Related Posts

News

Unvaccinated status increases risk of long COVID symptoms

January 29, 2023
News

Rezafungin is non-inferior to caspofungin in the treatment of candidemia and invasive candidiasis

January 28, 2023
News

An Analysis of HDL-bound Apolipoproteins in NAFLD Patients with Advanced Liver Fibrosis

January 27, 2023
News

Restrictive, Liberal Fluid Strategies Yield Similar Outcomes for Sepsis-Induced Hypotension

January 26, 2023
News

Mild to Moderate Cerebral Palsy in Young Children Treated with Vibration Therapy

January 25, 2023
News

Serrated Neoplasia Pathway to Colorectal Cancer Reveals Early Immune and Molecular Alterations

January 24, 2023
Next Post

Leveraging Digital Twins for Transforming Healthcare – The Health Care Blog

Recommended

And you thought Mastadons were extinct… – The Health Care Blog

3 months ago

Komodo Health Says “Big Pharma Needs to Kick Its Consulting Addiction” – The Health Care Blog

2 months ago

Julian Flannery, CEO, Summus – The Health Care Blog

2 months ago

USPSTF: Evidence Inadequate for Recommending OSA Screening

2 months ago

HHS’ $350M COVID-19 vaccine initiative

2 months ago

© 2022 Doctors News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

© 2022 Doctors News Hubb All rights reserved.